Navigation Links
Sorrento Therapeutics to Present at Two Healthcare Conferences
Date:9/6/2013

SAN DIEGO, Sept. 6, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC QB: SRNE; Sorrento) announced today that Dr. Henry Ji, President and CEO, will present a corporate overview at two upcoming conferences.

Rodman & Renshaw Annual Global Investment Conference
Sorrento is scheduled to present at the Annual Rodman & Renshaw Global Investment Conference at the Millennium Broadway Hotel in New York, NY on Tuesday, September 10, 2013 at 4:55 PM ET (Room 7.03). Dr. Ji will be available for one-on-one meetings during the conference.

Stifel Healthcare Conference 2013
Sorrento is scheduled to present at the Stifel Healthcare Conference at the Four Seasons Hotel in Boston, MA on Thursday, September 12, 2013 at 4:25 PM ET (Blaxton Room). Dr. Ji will be available for one-on-one meetings during the conference.

The presentation will be webcast live at http://www.veracast.com/stifel/healthcare2013/main/player.cfm?eventName=2145_sorren and can also be accessed through the investor relations page at www.sorrentotherapeutics.com. A replay of the presentation will be available at www.sorrentotherapeutics.com and will be archived for 90 days.

About Sorrento Therapeutics, Inc.

Sorrento Therapeutics, Inc. is a publicly-traded, development-stage biopharmaceutical company engaged in the acquisition, discovery, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs in the Unites States, Europe and additional international markets. Sorrento Therapeutics' primary therapeutic focus is oncology but it is also developing therapeutics products for other indications, including inflammation, metabolic, and infectious diseases. Sorrento Therapeutics' proprietary G-MAB® fully-human antibody library platform was designed to facilitate the rapid identification and isolation of highly specific antibody therapeutic product candidates that bind to disease targets appropriate for antibody therapy. Sorrento Therapeutics is also developing proprietary antibody drug conjugates (ADCs) as well as antibody formulated drug conjugates (AfDC) combining its G-MAB® antibodies and anti-tumor agents. On March 7, 2013, we entered into an exclusive option agreement with IgDraSol, Inc., a private company focused on developing oncologic agents for the treatment of metastatic breast cancer, or MBC, non-small cell lung cancer, or NSCLC, and other cancers.

More information is available at www.sorrentotherapeutics.com

Forward-Looking Statements

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Words such as "assumes," "plans," "believes," "expects," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements. Forward-looking statements include statements about the preclinical and clinical development of Sorrento's human antibody therapeutics. All such forward-looking statements are based on Sorrento's current beliefs and expectations, and should not be regarded as a representation by Sorrento that any of its plans will be achieved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in Sorrento's businesses; the scope and validity of patent protection for Sorrento's platform technologies, and the risk that the development or commercialization of product candidates may infringe the intellectual property rights of others; the potential that Sorrento may require substantial additional funding in order to obtain regulatory approval for and commercialize Sorrento Therapeutics' proprietary G-MAB® fully-human antibody library platform technologies or product candidates; and additional risks set forth in Sorrento Therapeutics' filings with the Securities and Exchange Commission. These forward-looking statements represent Sorrento Therapeutics' judgment as of the date of this release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and STI undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.


'/>"/>
SOURCE Sorrento Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sorrento Therapeutics and Ben-Gurion University Sign an Agreement for the Development of Anti-Hepatitis C Virus Antibodies
2. Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
3. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
4. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
5. Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City
6. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
7. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
8. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
9. Sorrento Therapeutics Awarded Third Phase I STTR Grant
10. Mast Therapeutics Hosting 2nd Annual Sickle Cell Disease Therapeutics Conference On September 19, 2013
11. Signature Therapeutics, Inc., Presents Four Scientific Posters Today at PAINWeek 2013 Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... CALABASAS, Calif. , June 14, 2017 ... with the City of Fremont ... chain of the bio-pharma industry in California ... sharing technology, enabling executive networking, and fostering workforce development. ... the development and growth of start-ups, as well as ...
(Date:6/11/2017)... -- Eli Lilly and Company (NYSE: LLY ) announced ... galcanezumab, an investigational treatment for the prevention of episodic ... secondary endpoints for galcanezumab compared to placebo at both ... and REGAIN) will be presented today at the American ... Boston . "The detailed Phase ...
(Date:6/8/2017)... , June 8, 2017  Less than a ... hit more than 200,000 companies, including hospital networks, in ... heralded as one of the largest online extortion attempts ... the healthcare market, it is imperative that providers understand ... their data from this — and many other very ...
Breaking Medicine Technology:
(Date:6/25/2017)... ... 2017 , ... With a heatwave currently bearing down on Northern California pushing temperatures to the ... swimsuit ready is easy with laser hair removal. , The process of summer waxing ... routine when all you want to do is get out, dive in and cool off. ...
(Date:6/24/2017)... Tampa, Fla. (PRWEB) , ... June 24, 2017 ... ... Fla., is now offering genetic testing for medications in select Florida and Texas ... of pharmacogenomics. , This new application of genetic testing recognizes the role ...
(Date:6/24/2017)... York (PRWEB) , ... June 24, 2017 , ... ... the Dental365 family. Located at 217 Portion Road in Lake Ronkonkoma, Dental365 offers ... evenings and weekends so that visits to the dentist fit into their patients’ ...
(Date:6/24/2017)... , ... June 24, 2017 , ... Doorknobs are for ... security, such as getting a guard dog or having an alarm system installed. But ... secure against forced entry. Yair Frenkel, owner of TX Premier Locksmith in Killeen, TX ...
(Date:6/23/2017)... , ... June 23, 2017 , ... ... is needed and will ultimately do significant harm to people with all chronic ... , "While it leaves in place the Affordable Care Act (ACA) requirement ...
Breaking Medicine News(10 mins):